Corporate ActionMay 12, 2026, 07:07 AM
Passage Bio Faces Going Concern Doubt, Initiates Strategic Review
AI Summary
Passage Bio, Inc. has reported substantial doubt about its ability to continue as a going concern, with current cash and cash equivalents of $33.3 million insufficient for the next 12 months. The company has initiated a review of strategic alternatives to maximize shareholder value, which may include mergers, acquisitions, asset sales, or partnerships. Despite an improved net loss of $7.6 million for Q1 2026 compared to $15.4 million in Q1 2025, the accumulated deficit reached $712.3 million.
Key Highlights
- Passage Bio faces substantial doubt about its ability to continue as a going concern.
- Company initiated a review of strategic alternatives to maximize shareholder value.
- Net loss for Q1 2026 improved to $7.6 million from $15.4 million in Q1 2025.
- Cash and cash equivalents decreased to $33.3 million as of March 31, 2026.
- Accumulated deficit increased to $712.3 million as of March 31, 2026.
- Recognized a net gain of $0.6 million on a lease termination in Q1 2026.
- Has $15.8 million capacity remaining under its ATM facility.
- A $5.0 million payment from Gemma Sublicenses due March 2026 has not yet been received.